Cart
sales@molnova.com
Ibrutinib deacryloylpiperidine
CAS No. 330786-24-8
Ibrutinib deacryloylpiperidine( IBT4A,5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine )
Catalog No. M22200 CAS No. 330786-24-8
Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | 35 | In Stock |
|
| 200MG | 50 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameIbrutinib deacryloylpiperidine
-
NoteResearch use only, not for human use.
-
Brief DescriptionIbrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
-
DescriptionIbrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
-
In Vitro——
-
In Vivo——
-
SynonymsIBT4A,5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBtk
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number330786-24-8
-
Formula Weight303.32
-
Molecular FormulaC17H13N5O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 25 mg/mL (82.42 mM)
-
SMILESNc3ncnc4nnc(c2ccc(Oc1ccccc1)cc2)c34
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.
molnova catalog
related products
-
BTK-IN-16
BTK-IN-16 is a potential inhibitor of wild-type BTK and C481S mutants.BTK-IN-16 can be used to study various autoimmune diseases and cancers caused by BTK.
-
Tirabrutinib
A potent, selective, third-generation irreversible inhibitor of mutant EGFR.
-
ARQ-531
ARQ-531 (ARQ531) is a potent, reversible, orally available inhibitor of both wild type and C481S-mutant BTK kinase with IC50 of 0.85 and 0.39 nM, respectively.
